Leukemia study restores silenced gene in mice. Could it point to new treatments for humans?
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 04:16 ET (22-Jun-2026 08:16 GMT/UTC)
Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, first-in-class drugs that inhibit hypoxia-inducible factors 1 and 2, a pair of transcription factors considered to be “master regulators” of cancer progression. The study, to be published April 2 in the Journal of Experimental Medicine (JEM), shows that these drugs, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice, suggesting that they could eventually be used to treat a broad range of cancers in humans.
A new study led by researchers at the University of Liège highlights the unexpected role of Stard7 in the development of intestinal cancers. Long seen as a transporter of some lipids to mitochondria, Stard7 now appears to be a key player in mitochondrial metabolism and tumour development in the intestine.
The National Comprehensive Cancer Network and NCCN Foundation select five Young Investigator Award recipients from Fred Hutchinson Cancer Center, Memorial Sloan Kettering Cancer Center, O'Neal Comprehensive Cancer Center at UAB, Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine, and The University of Texas MD Anderson Cancer Center.
As survival rates for female-specific cancers continue to rise, therapy-related myeloid neoplasms (t-MN) have become a critical long-term complication threatening survivors’ health. This systematic review by the team from Union Hospital summarizes the multi-factorial pathogenesis of t-MN, analyzes current treatment dilemmas, and puts forward female-focused management strategies. It provides a comprehensive theoretical framework for clinical precision prevention, early monitoring and targeted intervention of t-MN.